There has been a ton of consolidation in the med tech sector and one name that is always mentioned is Johnson & Johnson. A lot of speculation has been made about the state of their cardiology business, especially after cutting ties with their old Cordis division.
Analyst: Johnson & Johnson tables cardiology M&A – for now
Johnson & Johnson (NYSE:JNJ) yesterday signaled that it’s unlikely to pull the trigger on any merger & acquisition deals to bolster its cardiology business, according to a Leerink Partners analyst.
Worldwide chairwoman Sandi Peterson told Leerink’s Danielle Antalffy that the company has faith in its ability to “compete effectively” in cardiology with just two key operations in place, “which would imply no imminent acquisition in this space is likely,” according to an investors note sent out this morning.
Read story here at MassDevice
